compounded tirzepatide
Stop Doubling Semaglutide - When Compounded Tirzepatide Wins
In 2024, the FDA’s resolution of tirzepatide and semaglutide shortages underscores why patients should stop doubling semaglutide and consider compounded tirzepatide for more robust weight-loss outcomes. The combined use of both agents, often sourced from gray-market compounding pharmacies, creates an unregulated experiment that many clinicians are already observing in